Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival

efficacy and safety were evaluated after switching to a biosimilar infliximab (CPT-13) in patients with inflammatory bowel disease (IBD). However, few cohort studies compare the pharmacokinetic profiles, immunogenicity, and safety of the reference infliximab (IFX) and CPT-13 in a real clinical setti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Revista española de enfermedades digestivas 2021-11, Vol.113 (11), p.770
Hauptverfasser:	Iniesta Navalón, Carles, Gil Candel, Maite, Salar Valverde, Ignacio, Nicolás de Prado, Isabel, Gómez Espín, Rosa, Rentero Redondo, Lorena
Format:	Artikel
Sprache:	eng
Schlagworte:	Biosimilar Pharmaceuticals - therapeutic use Gastrointestinal Agents - therapeutic use Humans Inflammatory Bowel Diseases - drug therapy Infliximab - therapeutic use Pharmaceutical Preparations Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!